Differential in vitro immortalization capacity of eleven, probable high-risk human papillomavirus types

Journal of Virology

Volumn 88, Issue 3, 2014, Pages 1714-1724

  Schütze, Denise M ^a   Snijders, Peter J F ^a   Bosch, Leontien ^a   Kramer, Duco ^a,b   Meijer, Chris J L M ^a   Steenbergen, Renske D M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; E6 GENE; E7 GENE; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 70; IN VITRO STUDY; LIFE EXTENSION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRECANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA SPLICING; SPECIES DIFFERENTIATION; VIRAL GENE DELIVERY SYSTEM; VIROGENESIS; VIRUS IMMORTALIZATION; VIRUS ONCOGENE; VIRUS TRANSFORMATION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; FORESKIN; HUMANS; KERATINOCYTES; MALE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84892459642     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02859-13     Document Type: Article

References (63)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69-90. http://dx.doi.org/10.3322/caac.20107.
2. zur Hausen H. 2000. Papillomaviruses causing cancer: evasion from hostcell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92:690-698. http://dx.doi.org/10.1093/jnci/92.9.690.
3. Doorbar J. 2006. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 110:525-541. http://dx.doi.org/10.1042/CS20050369.
4. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. 2006. HPVmediated cervical carcinogenesis: concepts and clinical implications. J. Pathol. 208:152-164. http://dx.doi.org/10.1002/path.1866.
5. Burk RD, Chen Z, Van Doorslaer K. 2009. Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics 12:281-290. http://dx.doi.org/10.1159/000214919.
6. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348: 518-527. http://dx.doi.org/10.1056/NEJMoa021641.
7. International Agency for Research on Cancer. 2012. A review of human carcinogens. Biological agents. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 100 B. International Agency for Research on Cancer, Geneva, Switzerland.
8. Berkhof J, Bulkmans NW, Bleeker MC, Bulk S, Snijders PJ, Voorhorst FJ, Meijer CJ. 2006. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol. Biomarkers Prev. 15:1268-1273. http://dx.doi.org/10.1158/1055-9965.EPI-05-0764.
9. Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, Snijders PJ, Meijer CJ. 2007. High-risk HPV type-specific clearance rates in cervical screening. Br. J. Cancer 96:1419-1424. http://dx .doi.org/10.1038/sj.bjc.6603653.
10. Kjaer SK, Frederiksen K, Munk C, Iftner T. 2010. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl. Cancer Inst. 102: 1478-1488. http://dx.doi.org/10.1093/jnci/djq356.
11. Hiller T, Poppelreuther S, Stubenrauch F, Iftner T. 2006. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol. Biomarkers Prev. 15:1262-1267. http://dx.doi .org/10.1158/1055-9965.EPI-05-0778.
12. Mesplede T, Gagnon D, Bergeron-Labrecque F, Azar I, Senechal H, Coutlee F, Archambault J. 2012. p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J. Virol. 86:94-107. http://dx.doi.org/10.1128/JVI.00751-11.
13. Fu L, Van Doorslaer K, Chen Z, Ristriani T, Masson M, Trave G, Burk RD. 2010. Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity. PLoS One 5:e12816. http://dx.doi.org/10.1371/journal.pone.0012816.
14. Muench P, Hiller T, Probst S, Florea AM, Stubenrauch F, Iftner T. 2009. Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes. Virology 387:380-387. http://dx.doi.org/10.1016/j.virol.2009.02.018.
15. Steenbergen RD, de Wilde J, Wilting SM, Brink AA, Snijders PJ, Meijer CJ. 2005. HPV-mediated transformation of the anogenital tract. J. Clin. Virol. 32(Suppl 1):S25-S33. http://dx.doi.org/10.1016/j.jcv.2004.11.019.
16. Howie HL, Katzenellenbogen RA, Galloway DA. 2009. Papillomavirus E6 proteins. Virology 384:324-334. http://dx.doi.org/10.1016/j.virol.2008 .11.017.
17. Pim D, Banks L. 2010. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 118:471-493. http://dx.doi.org/10.1111/j.1600-0463.2010 .02618.x.
18. Fu B, Quintero J, Baker CC. 2003. Keratinocyte growth conditions modulate telomerase expression, senescence, and immortalization by human papillomavirus type 16 E6 and E7 oncogenes. Cancer Res. 63:7815-7824.
19. Shay JW, Wright WE. 2005. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 26:867-874. http://dx.doi.org/10.1093/carcin/bgh296.
20. Klingelhutz AJ, Barber SA, Smith PP, Dyer K, McDougall JK. 1994. Restoration of telomeres in human papillomavirus-immortalized human anogenital epithelial cells. Mol. Cell. Biol. 14:961-969.
21. Steenbergen RD, Walboomers JM, Meijer CJ, van der Raaij-Helmer EM, Parker JN, Chow LT, Broker TR, Snijders PJ. 1996. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene 13:1249-1257.
22. Doorbar J, Parton A, Hartley K, Banks L, Crook T, Stanley M, Crawford L. 1990. Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology 178:254-262. http://dx.doi.org/10.1016/0042-6822(90)90401-C.
23. Smotkin D, Prokoph H, Wettstein FO. 1989. Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J. Virol. 63:1441-1447.
24. Thomas M, Pim D, Banks L. 1999. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18:7690-7700. http://dx .doi.org/10.1038/sj.onc.1202953.
25. del Moral-Hernandez O, Lopez-Urrutia E, Bonilla-Moreno R, Martinez-Salazar M, Arechaga-Ocampo E, Berumen J, Villegas-Sepulveda N. 2010. The HPV-16 E7 oncoprotein is expressed mainly from the unspliced E6/E7 transcript in cervical carcinoma C33-A cells. Arch. Virol. 155:1959-1970. http://dx.doi.org/10.1007/s00705-010-0787-9.
26. Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Haas JA, Lowy DR, Schiller JT. 1991. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J. Virol. 65:4860-4866.
27. Tang S, Tao M, McCoy JP, Jr, Zheng ZM. 2006. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16-or type 18-positive cervical cancer cell lines via translation reinitiation. J. Virol. 80:4249-4263. http://dx.doi.org/10.1128/JVI.80.9 .4249-4263.2006.
28. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. 1995. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9:2335-2349. http://dx.doi.org/10.1101/gad.9.19.2335.
29. Stacey SN, Jordan D, Snijders PJ, Mackett M, Walboomers JM, Arrand JR. 1995. Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J. Virol. 69:7023-7031.
30. Pim D, Banks L. 1999. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene 18: 7403-7408. http://dx.doi.org/10.1038/sj.onc.1203134.
31. Pim D, Massimi P, Banks L. 1997. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 15:257-264. http://dx.doi.org/10.1038/sj .onc.1201202.
32. Kinsella TM, Nolan GP. 1996. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum. Gene Ther. 7:1405-1413. http://dx.doi.org/10.1089/hum.1996.7.12-1405.
33. van Zeeburg HJ, Snijders PJ, Pals G, Hermsen MA, Rooimans MA, Bagby G, Soulier J, Gluckman E, Wennerberg J, Leemans CR, Joenje H, Brakenhoff RH. 2005. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. Cancer Res. 65:1271-1276. http://dx.doi.org/10.1158/0008-5472.CAN-04-3665.
34. de Wilde J, De Castro Arce J, Snijders PJ, Meijer CJ, Rosl F, Steenbergen RD. 2008. Alterations in AP-1 and AP-1 regulatory genes during HPV-induced carcinogenesis. Cell Oncol. 30:77-87.
35. de Wilde J, Wilting SM, Meijer CJ, van de Wiel MA, Ylstra B, Snijders PJ, Steenbergen RD. 2008. Gene expression profiling to identify markers associated with deregulated hTERT in HPV-transformed keratinocytes and cervical cancer. Int. J. Cancer 122:877-888. http://dx.doi.org/10.1002/ijc.23210.
36. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A. 92:9363-9367. http://dx.doi.org/10.1073/pnas.92 .20.9363.
37. Henken FE, Oosterhuis K, Ohlschlager P, Bosch L, Hooijberg E, Haanen JB, Steenbergen RD. 2012. Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7. Vaccine 30:4259-4266. http://dx.doi.org/10.1016/j.vaccine.2012.04.013.
38. Steenbergen RD, Parker JN, Isern S, Snijders PJ, Walboomers JM, Meijer CJ, Broker TR, Chow LT. 1998. Viral E6-E7 transcription in the basal layer of organotypic cultures without apparent p21cip1 protein precedes immortalization of human papillomavirus type 16-and 18-transfected human keratinocytes. J. Virol. 72:749-757.
39. Chang YJ, Chen HC, Lee BH, You SL, Lin CY, Pan MH, Chou YC, Hsieh CY, Chen YM, Cheng YJ, Chen CJ. 2011. Unique variants of human papillomavirus genotypes 52 and 58 and risk of cervical neoplasia. Int. J. Cancer 129:965-973. http://dx.doi.org/10.1002/ijc.25724.
40. Xin CY, Matsumoto K, Yoshikawa H, Yasugi T, Onda T, Nakagawa S, Yamada M, Nozawa S, Sekiya S, Hirai Y, Shiromizu K, Fujii T, Taketani Y. 2001. Analysis of E6 variants of human papillomavirus type 33, 52 and 58 in Japanese women with cervical intraepithelial neoplasia/cervical cancer in relation to their oncogenic potential. Cancer Lett. 170:19-24. http://dx.doi.org/10.1016/S0304-3835(01)00570-5.
41. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27. http://dx .doi.org/10.1016/j.virol.2004.03.033.
42. International Agency for Research on Cancer. 2007. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 90. International Agency for Research on Cancer, Geneva, Switzerland.
43. McLaughlin-Drubin ME, Crum CP, Munger K. 2011. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl. Acad. Sci. U.S.A. 108:2130-2135. http://dx.doi.org/10.1073/pnas.1009933108.
44. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M. 2001. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 92:276-284. http://dx.doi.org/10.1002/ijc.1174.
45. Mansour M, Touka M, Hasan U, Bellopede A, Smet A, Accardi R, Gabet AS, Sylla BS, Tommasino M. 2007. E7 properties of mucosal human papillomavirus types 26, 53 and 66 correlate with their intermediate risk for cervical cancer development. Virology 367:1-9. http://dx.doi.org/10 .1016/j.virol.2007.05.005.
46. Howley PM. 1991. Role of the human papillomaviruses in human cancer. Cancer Res. 51:5019s-5022s.
47. Gewin L, Galloway DA. 2001. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J. Virol. 75:7198-7201. http://dx.doi.org/10.1128/JVI.75.15.7198-7201 .2001.
48. Oh ST, Kyo S, Laimins LA. 2001. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J. Virol. 75:5559-5566. http://dx.doi.org/10.1128/JVI.75.12.5559-5566.2001.
49. Veldman T, Liu X, Yuan H, Schlegel R. 2003. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. U.S.A. 100:8211-8216. http://dx.doi.org/10.1073/pnas.1435900100.
50. Van Doorslaer K, Burk RD. 2012. Association between hTERT activation by HPV E6 proteins and oncogenic risk. Virology 433:216-219. http://dx .doi.org/10.1016/j.virol.2012.08.006.
51. de Wilde J, Kooter JM, Overmeer RM, Claassen-Kramer D, Meijer CJ, Snijders PJ, Steenbergen RD. 2010. hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer 10:271. http://dx.doi.org/10.1186/1471-2407-10-271.
52. Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R. 2008. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology 375:611-623. http://dx.doi.org/10.1016/j.virol.2008.02.025.
53. Steenbergen RD, Kramer D, Meijer CJ, Walboomers JM, Trott DA, Cuthbert AP, Newbold RF, Overkamp WJ, Zdzienicka MZ, Snijders PJ. 2001. Telomerase suppression by chromosome 6 in a human papillomavirus type 16-immortalized keratinocyte cell line and in a cervical cancer cell line. J. Natl. Cancer Inst. 93:865-872. http://dx.doi.org/10.1093/jnci/93.11.865.
54. Miller J, Dakic A, Chen R, Palechor-Ceron N, Dai Y, Kallakury B, Schlegel R, Liu X. 2013. HPV16 E7 protein and hTERT proteins defective for telomere maintenance cooperate to immortalize human keratinocytes. PLoS Pathog. 9:e1003284. http://dx.doi.org/10.1371/journal.ppat.1003284.
55. Lace MJ, Anson JR, Klingelhutz AJ, Lee JH, Bossler AD, Haugen TH, Turek LP. 2009. Human papillomavirus (HPV) type 18 induces extended growth in primary human cervical, tonsillar, or foreskin keratinocytes more effectively than other high-risk mucosal HPVs. J. Virol. 83:11784-11794. http://dx.doi.org/10.1128/JVI.01370-09.
56. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford GM. 2012. Human papillomavirus types in 115,789 HPVpositive women: a meta-analysis from cervical infection to cancer. Int. J. Cancer 131:2349-2359. http://dx.doi.org/10.1002/ijc.27485.
57. Formentin A, Archambault J, Koushik A, Richardson H, Brassard P, Franco EL, Coutlee F. 2013. Human papillomavirus type 52 polymorphism and high-grade lesions of the uterine cervix. Int. J. Cancer 132: 1821-1830. http://dx.doi.org/10.1002/ijc.27874.
58. Niccoli S, Abraham S, Richard C, Zehbe I. 2012. The Asian-American e6 variant protein of human papillomavirus 16 alone is sufficient to promote immortalization, transformation, and migration of primary human foreskin keratinocytes. J. Virol. 86:12384-12396. http://dx.doi.org/10.1128/JVI.01512-12.
59. Richard C, Lanner C, Naryzhny SN, Sherman L, Lee H, Lambert PF, Zehbe I. 2010. The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer. Oncogene 29:3435-3445. http://dx.doi.org/10.1038/onc .2010.93.
60. Stanley M. 2006. Immune responses to human papillomavirus. Vaccine 24(Suppl 1):S16-S22. http://dx.doi.org/10.1016/j.vaccine.2005.09.002.
61. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. 2012. The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55-F70. http://dx.doi.org/10.1016/j.vaccine.2012.06.083.
62. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:335-340. http://dx.doi.org/10.1084/jem.179.1.335.
63. Bierkens M, Wilting SM, van Wieringen WN, van de Wiel MA, Ylstra B, Meijer CJ, Snijders PJ, Steenbergen RD. 2012. HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia. BMC Cancer 12:36. http://dx.doi.org/10.1186/1471-2407-12-36.